Released Sep 15, 2025, after the close
10-Q filed Sep 15, 2025, 46 days after period end · 0001654954-25-010775
Q3 2025 · 10-Q
Revenue$1.96M$1.96M −18.8% vs Q3 2024−18.8% vs Q2 2025
Net Income-$204.25K-$204.25K N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.01-$0.01 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$574,262−9.6%
Operating Income-$313,877N/M
Operating Cash Flow$236,524N/M
Free Cash Flowderived$234,488N/M
Margins · derived
Gross margin29.3%+3.0 pt vs Q3 2024
Operating margin-16.0%−0.2 pt vs Q3 2024
Net margin-10.4%+2.4 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $1.96M | $2.42M | $4.58M | $4.77M |
| Net Income | -$204.25K | -$309.19K | $526.24K | $288.03K |
| EPS Diluted | -$0.01 | $0.01 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR